When ever James Barder gives any news about FUM the share price goes down,because all he does is underline the fact that in 10 years we are still awaiting trial results,regulatory approval ,or shelf life difficulties.
James Barder, chief executive officer at Futura Medical PLC (LON:FUM) tells Proactive Investors the company has closed the recruitment of patients in its clinical study of MED2002, a gel the company has developed for the treatment of erectile dysfunction (ED). Barder expects the study to complete mid-summer, and to confirm that the treatment works faster than standard ED treatments like Viagra and is also safer for patients.
It's years since I sold out of this stock but I still check their financial filings and the figure that jumped out at me was the piffling 2015 revenues of below £30k - which wouldn't even cover their Blue Diamond website costs. The shelf life issue shouldn't affect online sales…although it will presumably be a factor if they have piles of unsold product.
Why would they be suspended? They have £4m in cash and a new customer order for CSD500 for H2. And are also in discussions with partners on the pain portfolio and Med2002 results on the way also which could provide another license agreement. This happens on AIM. Illiquid shares get overbought and oversold
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.